{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:57:23Z","timestamp":1793066243313,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP316901"],"award-info":[{"award-number":["APP316901"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["224215"],"award-info":[{"award-number":["224215"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG3364A1\/ 2"],"award-info":[{"award-number":["RG3364A1\/ 2"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.msard.2022.103561","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T02:12:40Z","timestamp":1643076760000},"page":"103561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression"],"prefix":"10.1016","volume":"59","author":[{"given":"Chunrong","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Simpson-Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Blizzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Louise","family":"Ponsonby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"van der Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2022.103561_bib0001","doi-asserted-by":"crossref","first-page":"e61110","DOI":"10.1371\/journal.pone.0061110","article-title":"Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis","volume":"8","author":"Almohmeed","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.103561_bib9002","doi-asserted-by":"crossref","unstructured":"Bjornevik, K., et al. (2022). \u201cLongitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.\u201d Science.","DOI":"10.1126\/science.abj8222"},{"issue":"3","key":"10.1016\/j.msard.2022.103561_bib0002","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/CMR.10.3.521","article-title":"Human herpesvirus 6","volume":"10","author":"Braun","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.msard.2022.103561_bib0003","doi-asserted-by":"crossref","unstructured":"Castellazzi, M., Delbue, S., Elia, F., Gastaldi, M., Franciotta, D., 2015. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. 2015, 901312.","DOI":"10.1155\/2015\/901312"},{"key":"10.1016\/j.msard.2022.103561_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: a review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"1","key":"10.1016\/j.msard.2022.103561_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","article-title":"Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI","volume":"73","author":"Farrell","year":"2009","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.103561_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2022.103561_bib0007","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.84.2.570","article-title":"Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection","volume":"84","author":"Henle","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.msard.2022.103561_bib0008","doi-asserted-by":"crossref","first-page":"e53996","DOI":"10.1371\/journal.pone.0053996","article-title":"Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study","volume":"8","author":"Horakova","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2022.103561_bib0009","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1352458519828667","article-title":"Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: a case-controlled magnetization transfer ratio study","volume":"26","author":"Jakimovski","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103561_bib8006","doi-asserted-by":"crossref","unstructured":"Kurtzke, J. F. (1983). \u201cRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).\u201d Neurology 33(11): 1444\u20131452.","DOI":"10.1212\/WNL.33.11.1444"},{"issue":"1","key":"10.1016\/j.msard.2022.103561_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1352458507080063","article-title":"Human herpes virus 6 and multiple sclerosis: a Finnish twin study","volume":"14","author":"Kuusisto","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103561_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1352458514533843","article-title":"Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis","author":"Kvistad","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103561_bib0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1743-422X-7-252","article-title":"Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dye","volume":"7","author":"Lay","year":"2010","journal-title":"Virology journal"},{"issue":"7","key":"10.1016\/j.msard.2022.103561_bib0013","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/1352458507077174","article-title":"Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function","volume":"13","author":"Lucas","year":"2007","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2022.103561_bib0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1212\/WNL.0b013e318227062a","article-title":"Current and past Epstein-Barr virus infection in risk of initial CNS demyelination","volume":"77","author":"Lucas","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2022.103561_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21886","article-title":"Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis","volume":"67","author":"Lunemann","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103561_bib0016","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21886","article-title":"Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis","volume":"67","author":"L\u00fcnemann","year":"2010","journal-title":"Ann. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2022.103561_bib0017","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","article-title":"Infectious mononucleosis","volume":"362","author":"Luzuriaga","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2022.103561_bib0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/eci.10.11","article-title":"Multiple sclerosis etiology: beyond genes and environment","volume":"6","author":"Mechelli","year":"2010","journal-title":"Expert review of clinical immunology"},{"issue":"19","key":"10.1016\/j.msard.2022.103561_bib0019","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1212\/WNL.0000000000002099","article-title":"No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT","volume":"85","author":"Munger","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2022.103561_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104836","article-title":"Anti-human herpesvirus 6A\/B IgG correlates with relapses and progression in multiple sclerosis","volume":"9","author":"Ortega-Madueno","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2022.103561_bib0021","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.103561_bib0022","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.103561_bib0023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.293.4.463","article-title":"Exposure to infant siblings during early life and risk of multiple sclerosis","volume":"293","author":"Ponsonby","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.msard.2022.103561_bib0024","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.msard.2013.12.004","article-title":"Multiple sclerosis therapy and Epstein-Barr virus antibody titres","volume":"3","author":"Raffel","year":"2014","journal-title":"Multiple sclerosis and related disorders"},{"issue":"7","key":"10.1016\/j.msard.2022.103561_bib0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(10)70094-6","article-title":"Multiple sclerosis: risk factors, prodromes, and potential causal pathways","volume":"9","author":"Ramagopalan","year":"2010","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.103561_bib0026","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.103561_bib0027","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ane.12268","article-title":"EBV & HHV6 reactivation is infrequent and not associated with MS clinical course","volume":"130","author":"Simpson","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.msard.2022.103561_bib0028","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/1352458511428081","article-title":"Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis","volume":"18","author":"Simpson","year":"2011","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2022.103561_bib0029","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/1352458511428081","article-title":"Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis","volume":"18","author":"Simpson","year":"2012","journal-title":"Mult. Scler."},{"issue":"7410","key":"10.1016\/j.msard.2022.103561_bib0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/bmj.327.7410.316","article-title":"Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study","volume":"327","author":"van der Mei","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.msard.2022.103561_bib0031","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13550280701381332","article-title":"Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications","volume":"13","author":"Virtanen","year":"2007","journal-title":"J. Neurovirol."},{"issue":"1","key":"10.1016\/j.msard.2022.103561_bib0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1352458513490545","article-title":"Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings","volume":"20","author":"Virtanen","year":"2014","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2022.103561_bib0033","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jmv.2158","article-title":"HHV-6 A- or B-specific P41 antigens do not reveal virus variant-specific IgG or IgM responses in human serum","volume":"66","author":"Xu","year":"2002","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.msard.2022.103561_bib0034","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp.2008.154906","article-title":"Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis","volume":"80","author":"Zivadinov","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:28:20Z","timestamp":1778840900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":36,"alternative-id":["S2211034822000761"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103561","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103561"}}